Drug Reimbursement Recommendation - Lorlatinib (Lorbrena) and Atezolizumab (Tecentriq)

Today, CADTH has issued final recommendations for:

Lorlatinib (Lorbrena) NSCLC

Funding Request: For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on: crizotinib and at least one other ALK inhibitor, or patients who have progressed on ceritinib or alectinib.
Recommendation: Do not reimburse
Notification to implement target date: February 14, 2020

For more information

Atezolizumab (Tecentriq) SCLC

Funding Request: For the first-line treatment of patients with extensive stage small cell lung cancer (ES-SCLC) in combination with a platinum-based chemotherapy and etoposide. Maintenance TECENTRIQ should be continued until loss of clinical benefit or unacceptable toxicity
Recommendation: Do not reimburse
Notification to implement target date: February 14, 2020

For more information